# mRNA platforms & LNP delivery Synthetic mRNA in lipid nanoparticles (60–100 nm) turns the cell into a bioreactor — from a vaccine platform to personalised cancer immunotherapy and in-vivo protein expression. Source: https://en.bioecon.ru/technology/mrna-platforms-lnp-delivery/ Updated: 2026-08-18 ## Overview and value chain Markers: [EC: ATMP Regulation (EC No 1394/2007) | OECD: Bio-Pharmaceuticals | Regulator: FDA (USA), EMA (EU), NMPA (China)] mRNA platforms with lipid-nanoparticle (LNP) delivery are a revolutionary biopharma paradigm: synthetic messenger RNA carries the genetic instruction straight into the cytoplasm, turning the cell into a bioreactor for therapeutic proteins, antigens or personalised neoantigens. Because "naked" mRNA is unstable, LNPs of 60–100 nm encapsulate it, enabling endocytosis and endosomal escape. An LNP has four lipids: ionizable (neutral at pH 7.4, positive in the endosome), PEG-lipid, phospholipid and cholesterol. After the COVID-19 breakthrough (Comirnaty, Spikevax), the sector is scaling into cancer vaccines and replacement protein therapy. Key directions of mRNA platforms: 1. **Infectious vaccines (Infectious Vaccines):** COVID-19, RSV, influenza — platform re-use of the LNP shell. 2. **Personalised cancer vaccines (Personalised Cancer Vaccines):** up to 34 neoantigens per patient (mRNA-4157). 3. **Self-amplifying RNA (Self-Amplifying RNA):** saRNA needs lower doses (ARCT-154). 4. **In-vivo protein expression & in-vivo CAR (In-Vivo Protein Expression):** rare-disease therapy and CAR-T without ex-vivo. ### Sectoral value chain ``` [DNA template] ──> [IVT transcription] ──> [mRNA purification] ──> [LNP assembly] │ (cell-free synthesis) │ ▼ [drug product] <─── [fill/lyophilisation] <─────┘ ``` ### Value chain levels | Level | Description | Key inputs/outputs | |:---|:---|:---| | **DNA Template** | plasmid DNA in E. coli + linearisation | **In:** strains, restriction enzymes. **Out:** linear DNA template. | | **IVT Transcription** | cell-free mRNA synthesis (T7, m1Ψ, NTPs) | **In:** template, T7, CleanCap. **Out:** raw mRNA. | | **mRNA Purification** | dsRNA removal (RP-HPLC) to >98% purity | **In:** raw IVT product. **Out:** pure mRNA. | | **LNP Formulation** | microfluidic self-assembly (pH 4.0) | **In:** mRNA, 4 lipids. **Out:** LNP emulsion. | | **TFF & Buffer Exchange** | ethanol removal, shift to pH 7.4 | **In:** LNP suspension. **Out:** neutral suspension. | | **Aseptic Fill & QC** | sterile fill, lyophilisation, release | **In:** suspension. **Out:** drug product (vial). | Cross-cutting technologies of the sector: - **Nucleotide modification (Nucleotide Modification):** N1-methylpseudouridine (m1Ψ) — 2023 Nobel — dampens innate immunity. - **Microfluidic mixing (Microfluidic Mixing):** herringbone mixers give PDI <0.1 and encapsulation >90%. - **Co-transcriptional capping (Co-transcriptional Capping):** CleanCap® — >95% Cap-1 in one step. --- ## US The US leads on mRNA capitalisation, patents and clinical scale-up, with mature CDMO infrastructure. ### Moderna leadership, CDMO infrastructure, FDA platform guidance - **Moderna:** mRNA-4157 (V940) + Keytruda — phase III melanoma recurrence reduction. - **CDMO + LNP components:** TriLink (CleanCap), Catalent, Lonza — full upstream capacity. - **FDA:** platform regulatory guidance — re-use of LNP-shell safety data across candidates. --- ## CN China treats mRNA as a biotech-sovereignty domain, localising the whole lipid and enzyme chain. ### Walvax/Abogen, raw-material localisation, Suzhou BioBAY hub - **Abogen/Walvax:** AWcorna and domestic mRNA vaccines; LNPs stable at +2–8°C. - **Localisation:** Yeasen — m1Ψ, T7 polymerase, ionizable lipids (SM-102/ALC-0315 analogues). - **BioBAY (Suzhou):** China's main mRNA cluster (hepatitis B, liver cancer, metabolic diseases). --- ## EU The EU is the birthplace of key nucleotide-modification and LNP discoveries, with strict ATMP regulation. ### BioNTech/CureVac phenomenon, EMA ATMP regulation - **BioNTech (Mainz):** Comirnaty (with Pfizer) + onco-pipeline; modular BioNTainer plants. - **CureVac:** oldest mRNA-stabilisation patent portfolio (GC optimisation, with GSK). - **EMA ATMP:** strict validation of dsRNA clearance and LNP-size stability under GMP. --- ## Leading companies and research institutes | Company / Institute | Country | Key products / platforms | Tech features | Status 2026 | |:---|:---|:---|:---|:---| | **Moderna** | 🇺🇸 USA | *Spikevax*, *mRNA-4157* (cancer vaccine) | AI codon design, proprietary lipids | Commercial | | **BioNTech** | 🇩🇪 Germany | *Comirnaty*, *BNT122* | neoantigens, BioNTainer plants | Commercial | | **CureVac** | 🇩🇪 Germany | gen-2 mRNA (with GSK) | codon optimisation of unmodified RNA | Operating | | **Arcturus** | 🇺🇸 USA | *LUNAR®*, *ARCT-154* (saRNA) | saRNA (low doses), biodegradable lipids | Commercial | | **Abogen** | 🇨🇳 China | *AWcorna* | thermostable LNPs (+2–8°C) | Operating | | **TriLink** | 🇺🇸 USA | *CleanCap®* | co-transcriptional capping >95% | Commercial | --- ## Tech stack and innovations The stack rests on cell-free synthesis, microfluidics and deep purification. 1. **IVT synthesis (In Vitro Transcription):** - T7 polymerase at 37°C, Mg^2+ cofactor; yield 5–10 g RNA/L. - full UTP→m1ΨTP replacement to bypass RIG-I/MDA5. 2. **Microfluidic LNP assembly (Microfluidic LNP Assembly):** - mixing lipids in ethanol with mRNA at pH 4.0; ethanol dilution triggers self-assembly. 3. **Deep RNA purification (Deep RNA Purification):** - RP-HPLC/HIC to remove dsRNA that drives interferon response. --- ## Value chains and production pipelines ### Industrial pipeline of mRNA-LNP production (GMP) ``` ┌───────────────────────────┐ ┌───────────────────────────┐ │ 1. DNA template (linear) │ ───> │ 2. IVT mRNA synthesis │ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 4. LNP assembly (microfl.)│ <─── │ 3. mRNA purification (HPLC)│ └───────────────────────────┘ └───────────────────────────┘ │ ▼ ┌───────────────────────────┐ ┌───────────────────────────┐ │ 5. TFF (ethanol removal) │ ───> │ 6. Fill & lyophilisation │ └───────────────────────────┘ └───────────────────────────┘ ``` #### Stage 1: DNA template Plasmid DNA (T7 promoter + poly-A 100–120 nt) is produced in E. coli and linearised with restriction enzymes. #### Stage 2: IVT synthesis The reactor is loaded with template, T7 polymerase, CleanCap and NTPs (UTP→m1ΨTP); 37°C, 2–4 h; DNase then removes the template. #### Stage 3: mRNA purification Ultrafiltration + RP-HPLC remove dsRNA; mRNA is transferred to pH 4.0 buffer and frozen at -80°C. #### Stage 4: LNP assembly Lipids in ethanol and mRNA at pH 4.0 are mixed in a microfluidic chip; the ionizable lipid binds the mRNA. #### Stage 5: TFF Tangential-flow filtration (100–300 kDa) removes ethanol and shifts the buffer to pH 7.4. #### Stage 6: Fill & lyophilisation Sterile 0.22 µm filtration, aseptic filling under nitrogen; lyophilisation with sucrose/trehalose; storage at -20…-80°C.